Ocular Therapeutix Inc. (OCUL)
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade
The consensus price target hints at an 82.9% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Analyst/Investor Day September 30, 2025 2:00 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Nadia Waheed - Chief Medical Officer Jeffrey Heier, - Chief Scientific Officer Namrata Saroj - Chief Business Officer Jay Robins Peter Kaiser - Chief Development Officer William Slattery - Vice President of Investor Relations Conference Call Participants Arshad Khanani - Sierra Eye Associates Eleonora Lad Adnan Tufail Patricio Schlottmann Tara Bancroft - TD Cowen, Research Division Biren Amin - Piper Sandler & Co., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Presentation Operator All right.
Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants Pravin U. Dugel - Executive Chairman, President & CEO William S.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.24 per share a year ago.
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
Why Ocular Therapeutix Was Bumping Higher This Week
The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company's stock higher.
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago.
Ocular Is Now Thoroughly Derisked
Ocular Therapeutics' OTX-TKI implant offers a cost-effective, long-lasting alternative to gene therapies for wet AMD, showing superior duration and comparable efficacy to Regeneron's Eylea. Recent FDA approval for trial modifications and positive phase 1 results in NPDR patients enhance OTX-TKI's potential, with phase 3 data expected by Q4 2025. Financially, OCUL is strong with a $1.34bn market cap and $427mn cash, ensuring a runway of 8-9 quarters despite high R&D expenses.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.51 per share a year ago.
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
